By Lipella Pharmaceticals|2023-01-12T18:36:34+00:00January 11th, 2023|Press Releases|Comments Off on Lipella Pharma Sees Positive Results for LP-10 Phase 2a Trial
By Lipella Pharmaceticals|2023-01-12T18:34:07+00:00December 19th, 2022|Press Releases|Comments Off on Lipella Pharmaceuticals Announces Pricing of Initial Public Offering of Common Stock
By Lipella Pharmaceticals|2022-09-15T13:07:57+00:00May 9th, 2022|Press Releases|Comments Off on Announcing Radiation (and Hemorrhagic) Cystitis Patient Registry
By Lipella Pharmaceticals|2022-09-15T13:06:49+00:00May 11th, 2021|Press Releases|Comments Off on Lipella Pharmaceuticals Announces Successful Completion of Pre-IND Type B FDA Meeting Regarding Oral Lichen Planus Drug Candidate
By Lipella Pharmaceticals|2022-09-15T13:05:40+00:00April 30th, 2021|Press Releases|Comments Off on Bladder Health Foundation Launches Patient Registry for Survivors of Pelvic Radiation Therapy
By Lipella Pharmaceticals|2022-09-15T13:04:14+00:00November 12th, 2020|Press Releases|Comments Off on National Bladder Awareness Month: A Look at the Facts about Pelvic Radiation Cancer Survivors
By Lipella Pharmaceticals|2022-09-15T13:02:38+00:00October 15th, 2020|Press Releases|Comments Off on Lipella Pharmaceuticals Initiates its Phase-2a Clinical Trial of LP-10 for Hemorrhagic Cystitis
Reach Out